AL Amyloidosis: The Prognostic Impact of Maintenance Therapy Following ASCT

Autologous stem cell transplantation (ASCT) remains an effective treatment option for many patients with systemic AL amyloidosis (AL). However, the decision to utilize maintenance therapy following ASCT remains controversial and largely unexplored. Furthermore, the growing relevance of cytogenetics in AL may help dictate this maintenance decision as well. It is also relevant to note the emergence of novel targeted therapy options for AL patients, including the plasma cell monoclonal antibody daratumumab, that offer an exciting option in combination therapies with ASCT.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Michael P. Ozga, Qiuhong Zhao, Don M. Benson, Patrick Elder, Nita Williams, Naresh Bumma, Ashley Rosko, Maria Chaudhry, Abdullah Khan, Srinivas Devarakonda, Rami Kahwash, Ajay Vallakati, Courtney Campbell, Samir Parikh, Salem Almaani, Jason Prosek, Elyse Tags: 342 Source Type: research